Shares of Xeris Pharmaceuticals Inc (NASDAQ:XERS) have received an average broker rating score of 1.25 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Analysts have set a one year consensus price objective of $26.50 for the company and are expecting that the company will post ($1.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Xeris Pharmaceuticals an industry rank of 110 out of 255 based on the ratings given to its competitors.

A number of brokerages recently weighed in on XERS. Zacks Investment Research downgraded shares of Xeris Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Jefferies Financial Group began coverage on shares of Xeris Pharmaceuticals in a research report on Monday, July 16th. They issued a “buy” rating and a $23.00 price target on the stock. Royal Bank of Canada began coverage on shares of Xeris Pharmaceuticals in a research report on Monday, July 16th. They issued an “outperform” rating and a $24.00 price target on the stock. Leerink Swann began coverage on shares of Xeris Pharmaceuticals in a research report on Monday, July 16th. They issued an “outperform” rating and a $24.00 price target on the stock. Finally, Mizuho began coverage on shares of Xeris Pharmaceuticals in a research report on Monday, July 16th. They issued a “buy” rating on the stock.

Shares of NASDAQ:XERS opened at $20.95 on Tuesday. Xeris Pharmaceuticals has a fifty-two week low of $15.75 and a fifty-two week high of $27.98.

Xeris Pharmaceuticals (NASDAQ:XERS) last announced its quarterly earnings results on Monday, August 13th. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($2.19). The company had revenue of $0.82 million for the quarter, compared to analyst estimates of $0.30 million. research analysts forecast that Xeris Pharmaceuticals will post -8.36 EPS for the current year.

In other Xeris Pharmaceuticals news, major shareholder Palmetto Partners, Ltd. bought 150,000 shares of the stock in a transaction that occurred on Monday, June 25th. The stock was acquired at an average cost of $15.00 per share, with a total value of $2,250,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider James E. Flynn bought 750,000 shares of the stock in a transaction that occurred on Monday, June 25th. The shares were acquired at an average cost of $15.00 per share, with a total value of $11,250,000.00. The disclosure for this purchase can be found here.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Granahan Investment Management Inc. MA bought a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $2,481,000. Redmile Group LLC bought a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $45,792,000. Dean Capital Investments Management LLC bought a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $563,000. Federated Investors Inc. PA bought a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $5,694,000. Finally, OppenheimerFunds Inc. bought a new position in shares of Xeris Pharmaceuticals during the 2nd quarter worth approximately $18,980,000. 45.89% of the stock is owned by institutional investors and hedge funds.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Xeris Pharmaceuticals (XERS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.